Literature DB >> 20164543

Serum markers of liver fibrosis: combining the BIPED classification and the neo-epitope approach in the development of new biomarkers.

Sanne Skovgård Veidal1, Anne-Christine Bay-Jensen, Gervais Tougas, Morten Asser Karsdal, Ben Vainer.   

Abstract

BACKGROUND: Fibrosis is a central histological feature of chronic liver diseases and is characterized by the accumulation and reorganization of the extracellular matrix. The gold standard for assessment of fibrosis is histological evaluation of a percutaneous liver biopsy. Albeit a considerable effort have been invested in finding alternative non-invasive approaches, these have not been sufficiently successful to replace biopsy assessment. AIM: To identify the extracellular matrix proteins of interest, that as protein degradation fragments produced during extracellular matrix metabolism neo-epitopes, may be targeted for novel biochemical marker development in fibrosis. We used the recently proposed BIPED system (Burden of disease, Investigative, Prognostic, Efficacy and Diagnostic) to characterise present serological markers.
METHODS: Pubmed was search for keywords; Liver fibrosis, neo-epitopes, biomarkers, clinical trail, extra cellular matrix, protease, degradation, fragment. RESULTS AND
CONCLUSION: Implementation of BIPED categorization in the development and validation of fibrosis biomarkers to simplify and standardize the use of existing and future biomarkers seems advantageous. In addition, a systematic use of the neo-epitope approach, i.e. the quantification of peptide epitopes generated from enzymatic cleavage of proteins during extracellular remodeling, may prove productive in the quest to find new markers of liver fibrosis.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20164543      PMCID: PMC3833336          DOI: 10.3233/DMA-2010-0678

Source DB:  PubMed          Journal:  Dis Markers        ISSN: 0278-0240            Impact factor:   3.434


  16 in total

Review 1.  Extracellular matrix remodeling: the common denominator in connective tissue diseases. Possibilities for evaluation and current understanding of the matrix as more than a passive architecture, but a key player in tissue failure.

Authors:  Morten A Karsdal; Mette J Nielsen; Jannie M Sand; Kim Henriksen; Federica Genovese; Anne-Christine Bay-Jensen; Victoria Smith; Joanne I Adamkewicz; Claus Christiansen; Diana J Leeming
Journal:  Assay Drug Dev Technol       Date:  2012-10-09       Impact factor: 1.738

2.  Asian-Pacific Association for the Study of the Liver (APASL) consensus guidelines on invasive and non-invasive assessment of hepatic fibrosis: a 2016 update.

Authors:  Gamal Shiha; Alaa Ibrahim; Ahmed Helmy; Shiv Kumar Sarin; Masao Omata; Ashish Kumar; David Bernstien; Hitushi Maruyama; Vivek Saraswat; Yogesh Chawla; Saeed Hamid; Zaigham Abbas; Pierre Bedossa; Puja Sakhuja; Mamun Elmahatab; Seng Gee Lim; Laurentius Lesmana; Jose Sollano; Ji-Dong Jia; Bahaa Abbas; Ashraf Omar; Barjesh Sharma; Diana Payawal; Ahmed Abdallah; Abdelhamid Serwah; Abdelkhalek Hamed; Aly Elsayed; Amany AbdelMaqsod; Tarek Hassanein; Ahmed Ihab; Hamsik GHaziuan; Nizar Zein; Manoj Kumar
Journal:  Hepatol Int       Date:  2016-10-06       Impact factor: 6.047

3.  Procollagen type I N-terminal propeptide (PINP) is a marker for fibrogenesis in bile duct ligation-induced fibrosis in rats.

Authors:  Sanne Skovgård Veidal; Efstathios Vassiliadis; Anne-Christine Bay-Jensen; Gervais Tougas; Ben Vainer; Morten Asser Karsdal
Journal:  Fibrogenesis Tissue Repair       Date:  2010-04-01

4.  Molecular serum markers of liver fibrosis.

Authors:  Tianhui Liu; Xiaoming Wang; Morten A Karsdal; Diana J Leeming; Federica Genovese
Journal:  Biomark Insights       Date:  2012-07-23

5.  MMP mediated degradation of type VI collagen is highly associated with liver fibrosis--identification and validation of a novel biochemical marker assay.

Authors:  Sanne Skovgård Veidal; Morten Asser Karsdal; Efstathios Vassiliadis; Arkadiusz Nawrocki; Martin Røssel Larsen; Quoc Hai Trieu Nguyen; Per Hägglund; Yunyun Luo; Qinlong Zheng; Ben Vainer; Diana Julie Leeming
Journal:  PLoS One       Date:  2011-09-14       Impact factor: 3.240

6.  Assessment of proteolytic degradation of the basement membrane: a fragment of type IV collagen as a biochemical marker for liver fibrosis.

Authors:  Sanne S Veidal; Morten A Karsdal; Arkadiusz Nawrocki; Martin R Larsen; Yueqin Dai; Qinlong Zheng; Per Hägglund; Ben Vainer; Helene Skjøt-Arkil; Diana J Leeming
Journal:  Fibrogenesis Tissue Repair       Date:  2011-10-05

7.  Future detection and monitoring of diabetes may entail analysis of both β-cell function and volume: how markers of β-cell loss may assist.

Authors:  Anita V Neutzsky-Wulff; Kim V Andreassen; Sara T Hjuler; Michael Feigh; Anne-Christine Bay-Jensen; Qinlong Zheng; Kim Henriksen; Morten A Karsdal
Journal:  J Transl Med       Date:  2012-10-30       Impact factor: 5.531

8.  Biglycan fragmentation in pathologies associated with extracellular matrix remodeling by matrix metalloproteinases.

Authors:  Federica Genovese; Natasha Barascuk; Lise Larsen; Martin Røssel Larsen; Arkadiusz Nawrocki; Yili Li; Qinlong Zheng; Jianxia Wang; Sanne Skovgård Veidal; Diana Julie Leeming; Morten Asser Karsdal
Journal:  Fibrogenesis Tissue Repair       Date:  2013-05-01

9.  Circulating levels of a collagen type v propeptide fragment in a carbon tetrachloride reversible model of liver fibrosis.

Authors:  E Vassiliadis; S S Veidal; C Hansen; M A Karsdal; D J Leeming
Journal:  Biomark Insights       Date:  2012-12-17

10.  Phosphodiesterase inhibition mediates matrix metalloproteinase activity and the level of collagen degradation fragments in a liver fibrosis ex vivo rat model.

Authors:  Sanne Skovgård Veidal; Mette Juul Nielsen; Diana Julie Leeming; Morten Asser Karsdal
Journal:  BMC Res Notes       Date:  2012-12-18
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.